Although some people with plaque psoriasis can control their symptoms by using topical treatments that are applied to the skin, some people with moderate or severe plaque psoriasis do not get enough ...

Although some people with plaque psoriasis can control their symptoms by using topical treatments that are applied to the skin, some people with moderate or severe plaque psoriasis do not get enough ...

Please provide your email address to receive an email when new articles are posted on . Bimzelx (bimekizumab-bkzx) is the first and only interleukin 17A and 17F inhibitor approved in this indication.

Janssen Pharmaceuticals, Inc., a Johnson & Johnson company, announced new Phase 3b topline Week 16 results from Cohort A of the VISIBLE trial, the first prospective, large-scale, randomized-controlled ...

Recent advances in molecular and pathobiology have brought the field of dermatology to the cusp of reaching a goal that seemed highly improbable or impossible just a few years ago: a cure for plaque ...

Please provide your email address to receive an email when new articles are posted on . The proportion of deucravacitinib-treated patients that reported no quality-of-life impact increased from 0% at ...

Deucravacitinib demonstrated stable or decreased adverse event rates over three years, with sustained clinical efficacy in plaque psoriasis patients. The study included 1519 patients, with 513 ...

Bimzelx is available as a single-dose prefilled autoinjector or prefilled syringe containing 160mg/mL of solution. Bimzelx ® (bimekizumab-bkzx) is now available for the treatment of moderate to severe ...

Portia has not taken Sotyktu. Portia Brown* has long been drawn toward helping people cope with challenges. Since volunteering as a college student to work with her peers to educate them about sexual ...

Working on fast cars has been Rogelio "Al" Castro's lifelong passion. Now, in retirement, he loves to take his grandkids to the speedway and tell them what it was like when he worked in the pit - the ...